2024

Bourgonje AR, Dubinsky MC, Keizer RJ, Dreesen E, Mian P. Model-informed precision dosing in inflammatory bowel diseases. Trends Pharmacol Sci 2024; in press.

Bourgonje AR, Ungaro RC, Mehandru S, Colombel JF. Targeting the IL-23 Pathway in Inflammatory Bowel Disease. Gastroenterology 2024; S0016-5085(24)05124-2. doi: 10.1053/j.gastro.2024.05.036.

Blok EL, Burger RJ, van Bergeijk JE, Bourgonje AR, van Goor H, Ganzevoort W, Gordijn SJ. Oxidative stress biomarkers for fetal growth restriction in umbilical cord blood: A scoping review. Placenta 2024;154:88-109. doi: 10.1016/j.placenta.2024.06.018.

2023

Loveikyte R, Bourgonje AR, van Goor H, Dijkstra G, van der Meulen-de Jong AE. The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: A review on the conundrum. Redox Biol 2023;68:102950. doi: 10.1016/j.redox.2023.102950.

Geertsema S, Bourgonje AR, Fagundes RR, Gacesa R, Weersma RK, van Goor H, Mann GE, Dijkstra G, Faber KN. The NRF2/Keap1 pathway as therapeutic target in inflammatory bowel disease. Trends Mol Med 2023;S1471-4914(23)00158-2. doi: 10.1016/j.molmed.2023.07.008.

Bourgonje AR, van Goor H, Faber KN, Dijkstra G. Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities. Clin Transl Gastroenterol 2023;14(7):e00579. doi: 10.14309/ctg.0000000000000579.

Bourgonje AR, Grochot-Przeczek A, Kloska D, Feelisch M, Cuadrado A, van Goor H. Personalized redox medicine in inflammatory bowel disease: emerging role of HIF1α and NRF2 as therapeutic targets. Redox Biol 2023;60:102603. doi: 10.1016/j.redox.2023.102603.

2022

van Eijk LE, Offringa AK, Bernal ME, Bourgonje AR, van Goor H, Hillebrands JL. The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19). Adv Exp Biol Med 2022;1370:3-21. doi: 10.1007/978-3-030-93337-1_1.

Bourgonje AR, Vogl T, Segal E, Weersma RK. Antibody signatures in inflammatory bowel disease: current developments and future applications. Trends Mol Med 2022;28(8):693-705. doi: 10.1016/j.molmed.2022.05.004.

2021

Offringa AK, Bourgonje AR, Schrier MS, Deth RC, van Goor H. Clinical implications of vitamin B₁₂ as redox-active cofactor. Trends Mol Med 2021;27(10):931-934. doi: 10.1016/j.molmed.2021.07.002.

Bourgonje AR, Offringa AK, van Eijk LE, Abdulle AE, Hillebrands JL, van der Voort PHJ, van Goor H, van Hezik EJ. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019. Antioxid Redox Signal 2021;35(14):1207-1225. doi: 10.1089/ars.2020.8247.

van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, Kolundzic N, Abdulle AE, van der Voort PHJ, Olde Rikkert MGM, van der Hoeven JG, den Dunnen WFA, Hillebrands JL, van Goor H. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J Pathol 2021;254(4):307-331. doi: 10.1002/path.5642.

2020

Bourgonje AR, Feelisch M, Faber KN, Pasch A, Dijkstra G, van Goor H. Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease. Trends Mol Med 2020;26(11):1034-1046. doi: 10.1016/j.molmed.2020.06.006.

Bourgonje AR^*, Abdulle AE^*, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus ADME, van der Voort PHJ, Mulder DJ, van Goor H. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 2020;251(3):228-248. doi: 10.1002/path.5471.

Leimkühler M, Bourgonje AR, van Goor H, van Leeuwen BL, de Bock GH. Systemic oxidative stress and antioxidant capacity in cancer patients. J Transl Sci 2020;6:372. doi: 10.15761/JTS.1000372.

2017

von Martels JZH, Sadaghian Sadabad M, Bourgonje AR, Blokzijl T, Dijkstra G, Faber KN, Harmsen HJM. The role of gut microbiota in health and disease: In vitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. Anaerobe 2017;44:3-12. doi: 10.1016/j.anaerobe.2017.01.001.